Vulcan Materials reports strong Q3 growth, expects 3% shipment rise and $2.4B EBITDA for 2025 amid infrastructure spending and favorable market conditions.
Probe by former Special Counsel Jack Smith targets over 430 Republicans, raising concerns about political surveillance and partisan 'fishing expedition'.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Vulcan Materials reports strong Q3 growth, expects 3% shipment rise and $2.4B EBITDA for 2025 amid infrastructure spending and favorable market conditions.
Probe by former Special Counsel Jack Smith targets over 430 Republicans, raising concerns about political surveillance and partisan 'fishing expedition'.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.